Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

111.94 -0.01 (-0.01%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
Patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug Wegovy, were less than half as likely to overdose. 
Via Benzinga
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
2seventy bio halts enrollment in its KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval... 
Via Benzinga
Exposures Product Safety
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on company's bottom line. 
Via Benzinga
Novo Nordisk To Consider Ways For Patients To Affordably Access Weight Loss Drugs Ozempic, Wegovy, Says CEO
Novo Nordisk CEO commits to exploring ways to make weight-loss drugs more affordable for U.S. patients after hearing from Congress. 
Via Benzinga
Novo Nordisk's Options: A Look at What the Big Money is Thinking
Via Benzinga
Novo Nordisk's Options: A Look at What the Big Money is Thinking
Via Benzinga
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Via Benzinga
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now? 
Via MarketBeat
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
From Aligos Therapeutics
Via GlobeNewswire
'Miracle' Weight Loss Drug Ozempic To Enter US Price Negotiations Within A Year, Novo Nordisk CEO Says Ahead Of Senate Hearing
Last week, another Novo executive indicated that Ozempic would "very likely" be included in the 2027 list. 
Via Benzinga
2 Weight-Loss Stocks That Could Rocket Higher This Year
Upcoming clinical trial results could push these stocks through the roof before 2024 is finished. 
Via The Motley Fool
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now
Corbus Pharmaceuticals received buy ratings from H.C. Wainwright and Oppenheimer, citing the company's diversified pipeline. 
Via Benzinga
Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday
Novo Nordisk CEO Lars Fruergaard Jørgensen faces a Senate hearing led by Bernie Sanders over the high cost of Ozempic and Wegovy, as U.S. lawmakers push for drug price reductions. 
Via Benzinga
Bernie Sanders Questions Why Your Monthly Ozempic Prescription Costs More Than A Luxury Handbag When It Can Be Sold For Less Than $100
Via Benzinga
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% 
Via Benzinga
3 Stocks That Could Rise on European Bank Interest Rate Cuts
The European Central Bank cut interest rates for the second time in about three months prior the FOMC's interest rate announcement, European stocks may benefit. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
NFLX is among four stocks on the list that's actionable now. 
Via Investor's Business Daily
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout. 
Via The Motley Fool
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
FTC files a complaint against CVS, Cigna, and UnitedHealth's PBMs, accusing them of inflating insulin prices through a rebate-driven system. The case aims to address unfair practices and improve access... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose. However, investors reacted to limited gains at higher doses. Corbus... 
Via Benzinga
Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk's Cannabinoid-Based Weight Loss Drug Trial Disappoints
Corbus Pharmaceuticals and Novo Nordisk stocks plunge following cannabinoid receptor drug trials, raising concerns over weight loss results. 
Via Benzinga
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients
Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 mg daily dose compared to placebo. 
Via Benzinga
Novo Dives — And Corbus Crashes — After New Weight-Loss Drug Causes Neuropsychiatric Effects
Shares of Corbus, which is working on a similar drug, also crashed on Novo Nordisk's news. 
Via Investor's Business Daily
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with... 
Via Benzinga
Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel
Hims & Hers Health will offer compounded GLP-1 weight-loss medications for as low as $99 per month to eligible U.S. military personnel, veterans, teachers, nurses, and first responders. The telehealth... 
Via Benzinga
Viking Therapeutics Is Having a Year to Remember: Time to Buy?
Viking Therapeutics Inc. (NASDAQ: VKTX) has surged 238% year-to-date and 326% over the past year, far outpacing its sector and market. 
Via MarketBeat
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
This strategic play will take time to pay off, but it could keep growth going. 
Via The Motley Fool
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications
Wednesday, Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the ... 
Via Benzinga
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Telemedicine once seemed like it was going to revolutionize healthcare. 
Via The Motley Fool
2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200
No need to break the bank to get in on these excellent companies. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.